ESIC€¦ · esic central rate contract no. -142 for supply of drugs & dressings (valid from 3rd may, 2018 to 2"d may, 2020) drugs for gastro intestinal system drugs for musculo-skeletal

ESIC CENTRAL RATE CONTRACT NO. -142

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020)

DRUGS FOR GASTRO INTESTINAL SYSTEM DRUGS FOR MUSCULO-SKELETAL DISORDERS & TISSUE

INFLAMMATION DRUGS FOR EYE & ENT

STRICTLY FOR OFFICIAL USE

EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN

C.I.G. ROAD, NEW DELHI-110 002

ESIC CENTRAL RATE CONTRACT NO. -142

FOR SUPPLY OF DRUGS & DRESSINGS

(VALID FROM 3rd MAY, 2018 to 2nd MAY, 2020)

DRUGS FOR GASTRO INTESTINAL SYSTEM DRUGS FOR MUSCULO-SKELETAL DISORDERS & TISSUE

INFLAMMATION DRUGS FOR EYE & ENT

[ . STRICTLY FOR OFFICIAL USE

PUBLISHED BY

DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION

ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI-110 002

Sno. Contents Page No.

1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A).

r

2. List of Approved Pharmaceutical firms. 1

3. Address with Terms & Conditions of the 1-5 Eligible firms

4. Index 1-2

5. Rate Schedule 1-13

REGISTERED STRICTLY FOR OFFICIAL USE ONLY

HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION

PANCHDEEP BHA WAN: C.I.G. ROAD: NEW DELHI -110 002 TeiFax: 011-23234334, E-mail: [email protected], dmc.rc.esic@qmail,com

(An IS0-9001 :2008 Certified)

No.U-25/12/142/2017-Med. V/RC 142 Dated: 3'a May, 2018

From:

To

The Director General, E.S.I. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI - 110 002.

The Director, ESI Scheme- All States Medical Superintendent- ESIC Model Hospitals

Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 142 EFFECTIVE FROM 03.05.2018 TO 02.05.2020.

Sir I Madam,

Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, 03.05.2018. Further, the following instructions are issued to govern operation of the Rate Contract.

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

I

2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof.

3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.

4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

SUPPLIES

5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through email followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone.

6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.

7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.

8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The

II

Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract

9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.

10. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract.

11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.

12. in all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.

14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

III

15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials,

bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected.

b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.

c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to

IP I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic

bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of

uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.

g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.

h) Packing should be able to prevent damage or deterioration during transit.

i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents.

j) It should be ensured that lSI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lSI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.

16. Life Period : a) For Drugs having shelf life of Two years or less: Drug supplied

should not be older than one fourth (1/4) of its shelf life from the date of manufacture.

b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture.

c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply.

17. Pharmacopoeia Specifications : Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act.

IV

18. Testing of Drugs - Quality Control a) Approved Rate Contract Holder should submit a Test Report

that particular batch of medicines tested by the Government! Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply.

b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.

c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs.

d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory.

e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the

v

particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed.

f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier.

The classification of defects into diff~rent categories is as per the guidelines issued by the Drug Controller of India & action will be taken by ESIC for each category of defects, described as under:-

A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)-lf any item I Batch of the item declared Not of Standard quality (NSQ) under Category A . • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.

• Forfeiture of Performance Security from the respective DGESIC Rate Contract.

• Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B

• Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already.


• Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of

VI

any adverse reaction reported in the Hospital during administration of the drugs.

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category B within a year • Recall of the NSQ item immediately from all ESIC/ ESIS User

Units. Recoveries to be initiated by the DDO's wherever payment had been made already.



• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years.

• Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C





VII

II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year




• Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years


19. Delivery Period - Risk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within

the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 1 0% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of deliverv period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.

c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the

VIII

pharmaceutical firm, in full at discretion of Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years.

d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate.

20. Payment a. Payment may be made directly to the firm. Payment for the supply will

be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract

b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions.

IX

c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding.

d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever.

e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm.

f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit.

21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts.

22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: -1. The Contractor shall be liable to be debarred for supplying

medicines I drugs etc. to the Corporation for a period not exceeding five years.

ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply

The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:-

PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O.No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if

Drug Date penalty pending levied

1. 2. 3. 4. 5. 6. 7. 8.

X

24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

25. No other document should be entertained for giving any cognizance for placing the supply orders.

26. Acceptance letter issued to the firms by this office cannot be used for placing orders.

Receipt of this letter may please be acknowledged.

Encl.: As above.

Copy to:

Yours faithfully,

(Dr.~ Logani) Dy. Medical Commissioner (RC)

For: DIRECTOR GENERAL

1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.

2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States)

DY. MEDI~~MISSIONER (RC)

XI

Approved Vendor list

SNO. FIRM NAME

1 ABBOTT HEALTHCARE PRIVATE LIMITED

2 ABBOTT INDIA LIMITED

3 AJANTA PJ-IARMA L TO,,

4 ALCON LABORATORIES (INDIA) PRIVATE LIMITED

5 BAYER ZYDUS PJ-IARMA PRIVATE LIMITED

6 C/PLA LTD

7 CORONA REMEDIES PVT LTD

8 EMCURE PHARMACEUTICALS LIMITED

9 GLAXOSMITHKLINE PHARMACEUTICALS LTD

10 GLEN MARK PHARMACEUTICALS LIMITED

11 JOHNSON & JOHNSON PRIVATE LIMITED

12 MICRO LABS LTD

13 OVERSEAS HEALTH CARE PVT LTD

14 PSYCHOTROPICS INDIA LIMITED

15 SANOFIINDIA LIMITED

16 TABLETS (INDIA} LIMITED

17 TORRENT PHARMACEUTICALS LTD

18 TROIKAA PHARMACEUTICALS LIMITED

19 USV PRIVATE LIMITED

20 WALLACE PHARMACEUTICALS PVT LTD

Page 1 of 1

Vendor Name

Abbott Healthcare Private limited

Floor 17, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai-400051 Maharashtra

Tel: 022-2238160527, 7777020398

Term 1

Term 2

Term 3

Term4

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.

If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled.

Supply to be made directly.

Email: [email protected] & [email protected]

Vendor Name

Abbott India Limited

Floor 16, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai-400051 Maharashtra

Tel: 022-2238160527, 7777020398

Term 1

Term 2

Term 3

Term4

Delivery within 6(six) weeks (of the actual date of

dispatch) of supply order on FOR Destination basis GST as applicable will be extra except for items where no tax has been approved.




Vendor Name

Ajanta Pharma Ltd.,

Ajanta House 98 Govt. Industrial Estate Charkop Kandivali West Mumbai Maharashtra- 400067

Tel: 022-66061202, 66061221, 66061200,66061300

Email: [email protected]

Vendor Name

ALCON LABORATORIES {INDIA) PRIVATE LIMITED 3rd Floor, Crescent 4, Prestige Shantiniketan, Whitefield BANGALORE-560048,KARNATAKA

Tel: 8040064600, 9008528787


Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

Page 1 ofS

Delivery within 6(six) weeks (of the actual date of dispatch) of supply order on FOR Destination basis

GST as applicable will be extra except for items where no tax has been approved.







Vendor Name

Bayer Zydus Pharma Private Limited 5th Floor, Bayer House, Central Avenue, Hiranandani Estate, Thane(W)-400607

Tel: 2225311710, 2225455078 9819358800

Term 1

Term 2

Term 3

Term4


Vendor Name

Cipla Ltd

Cipla Limited, Mumbai Central, Mumbai-400008 Maharastra

Tel: 8879967909


Vendor Name

Corona Remedies Pvt ltd

Corona House, C- Mandel Business Park Near Gurudwara S.G. Highway, Thaltej Ahmedabad Gujarat-380059

Tel: 079 40233000/65426663


Vendor Name

Emcure Pharmaceuticals Limited

Emcure House Plot No. 184, MIDC Bhosari Pune- 411026 Maharashtra

Tel: 2039192761


Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4

Page 2 ofS



If at any time documents submitted/ information given by the firm in the tender is found to be false/ erroneous, the award will be cancelled. Supply to be made directly.





Delivery within 6(six) weeks (ofthe actual date of dispatch) of supply order on FOR Destination basis








Vendor Name

GlaxoSmithKiine Pharmaceuticals Ltd GSK House, Dr.Annie Besant Road, Worli Mumbai-400030 Maharashtra

Tel: 022-24959249, 022-24959494, 9920898316

Term 1

Term 2

Term 3

Term4






Vendor Name

GLEN MARK PHARMACEUTICALS LIMITED GLEN MARK HOUSE, B D SA WANT MARG, Chakala, ANDHERI (EAST) MUMBAI MAHARASHTRA-400099

Tel: 22-40888925/927, 22-40189988, 09324291478

Term 1

Term 2

Term 3

Term 4


Vendor Name

Johnson & Johnson Private Limited

8th Floor, ARENA SPACE OFF JVLR BEHIND MAJAS DEPOT, JOGESHWARI EAST MUMBAI MAHARASHTRA-400060

Tel: 22 61087103, 022 66718200, 09892101039


Vendor Name

MICRO LABS LTD

No. 27, RACE COURSE ROAD, BANGALORE KARNATAKA 560001

Tel: 080-22256323, 22370463

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term4











Page 3 of5

Vendor Name

OVERSEAS HEALTH CARE PVT LTD

335 KM MILESTONE, NH N0.1, P.O.BOX-25 PHILLAUR- 144410 PUNJAB

Tel: 01826-222886, 01826-222885, 9872019733


Vendor Name

PSVCHOTROPICS INDIA LIMITED

PLOT NO. 17 SECTOR- 20 A, FARIDABAD- 121001 FARIDABAD HARYANA Tel: 0129-2296764


Vendor Name

Sanofi India Limited

Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai- 110072

Tel: 022-28032000, 28032939


Vendor Name

TABLETS (INDIA) LIMITED

Jhaver Centre, IV Floor, Raja Annamalai Building, 72, Marshalls Road, Egmore, Chennai-600008

Tel: 044-42050000, 28589090, 9380106636


Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term4

Page 4 ofS














Vendor Name

TORRENT PHARMACEUTICALS LTD

TORRENT HOUSE, OFF ASHRAM ROAD AHMEDABAD GUJARAT 380009

Tel: 079 26585090 I 3060

Term 1

Term 2

Term 3

Term4





Vendor Name

TROIKAA PHARMACEUTICALS LIMITED Commerce House- 1, Satya Marg, Bodakdev, Ahmedabad-380054 Gujarat

Tel: 079-26856242 I 43 I 45 I 46, 9879615617


Vendor Name

USV Private Limited

Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai- 400088 Maharashtra

Tel: 022-25564048


Vendor Name

WALLACE PHARMACEUTICALS PVT LTD

B 307-312 FLORAL DECK, PLAZA. OFF CENTRAL MIDC ROAD, ANDHERI (EAST), MUMBAI MAHARASHTRA 400093

Tel: 022-29261152, 022-28390733, 9820360019

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4

Term 1

Term 2

Term 3

Term 4













Page 5 of 5

----·· - -----·---~-~-~----- .. ---RC 142 (Index) ----

Item

Sno. No. Item Name and Description Unit Page No.

RABEPRAZOLE SODIUM 20mg + MOSAPRIDE CITRATE lSmg sustained release

1 1496 CAP 1 cap. 1

LANSOPRAZOLE 1SMG TAB/CAP- Each orally disintegrated Tab /cap to

2 2009 contain: Lansoprazole 15mg (as Enteric Coated pellets) 1 Tab/Cap 1

2053 Rabeprazole Sodium IP 20 mg (as enteric coated pellets) Domperidone IP 30

3 mg (as sustained release pelletes) Tab 1 cap. 1

4 1822 LACTULOSE SYP - Each 15m I to contain : Lactulose 10gm

200ml bot 2

5 1823 LACTULOSE SYP- Each 15m I to contain : Lactulose 10gm 450ml bot 2

ANTISPASMODIC DROPS/SUSPENSION - Each mi. to contain: Dicyclomine Hcl

6 16 10 mg, Activated Dimethicone 40mg. 10 mi. Bot. 2

DICYCLOMINE +MEFENAMIC TAB- Each Tab to contain: Dicyclomine lOmg.,

7 1346 Mefenamic Acid 250mg. 1 Tab 3

8 2056 Chlordiazepoxide Smg, Clidinium Bromide 2.5mg Tab 1 tab 3

LIVER DISORDERS SYP • Each 15m I contains: DL-Methionine BP 100mg,

Choline Dihydrogen Citrate NFX11100mg, L·Leucine USP 19mg, L-lsoleucine

USP 10mg ,L-Valine USP11mg, Pyridoxine HciiP l.Smg, Nicotinamide IP

22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg,

9 1991 Inositol BP SOmg 200ml bot 3

LIVER DISORDERS TAB- Each tab to contain: DL-Methionine BP 200mg,

Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-lsoleucine

USP 10mg, L-Valine USP 11mg, Pyridoxine Hydrochloride IP

l.Smg,Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5 mg,

10 1992 Cyanocobalamin IP 3.0 meg, Inositol BP 50 mg 1 tab 4

11 577 URSODESOXYCHOLIC ACID 150mg TAB 1 tab 4

12 2057 Ursodoxycholic Acid 300mg Tab 1 tab 5

13 2058 Pancreatin 170mg Activated Dimethicone 80mg tab 1 tab 5

HAEMORRHOIDAL CREAM- Containing: Beclomethasone dipropionate 0.025 20gm

14 358 %, Phenylepherine Hydrochloride 0.1 %, Lignocaine hydrochloride 2.5 %. Tube 5

1856 TRAMADOL AND PARACETAMOL TAB/ CAP- Each tab/cap to

15 contain:Tramadol 37.50 mg, Paracetamol325mg 1 tab/ cap 6

1093 IBUPROFEN AND PCM ORAL SUSP- Each 5 ml to contain: Ibuprofen 100 mg.,

16 Paracetamol162.5 mg. 60ml bot 6

17 1376 HYDROXY CHLOROQUINE 200mg TAB 1 tab 7

18 1675 LORNOXICAM SR 16mg TAB 1 tab 7

Page 1 of 2

~---- ----~--·~--- --

RC 142 (Index) --

Item

Sno. No. Item Name and Description Unit Page No.

19 1862 FEBUXOSTAT TAB- Each tab to contain: Febuxostat 40mg 1 tab 8

20 2024 PARACETAMOL 650MG TAB 1 tab 8

21 2082 Dexketoprofen 25mg + Paracetamol 325mg Tab ltab 8

Aflibercept injection 40 mg I miAflibercept (r-DNA Origin) solution for

intravitreal injection in Via lEach pack contains: 1 vial and a 18 G Sterile filter

needle 278 microliters/vial Each single dose vial provides a usable amount to

22 2083 deliver a single dose of 50 microliters containing 2mg Aflibercept 1 vial 9

ANALGESIC CREAM : Methyl salicylate 30% w/w, Menthol10% w/w,

23 1866 Camphor 4% w/w Excipients q.s. 30 gm tube 9

24 1432 OLOPATADIN EYE DROP- Each vial: Olopatadin l.Omg

5mlvial 9

DORZOLAMIDE+TIMOLOL EYE DROP- Each vial to contain: Dorzolamide 2% 1601

,Timoloii.P. 0.5% 25 5mlvial 10

CARBOXY METHYL CELLULOSE EYE DROP- Each ml to contain: Sodium 1923

Carboxy methyl cellulose Smg 26 10m I vial 10 - - --27 1924 DORZOLAMIDE EYE DROP- Each vial: Dorzolamide 2% 5mlvial 10

28 1228 ACYCLOVIR EYE OINT- Each tube to contain: Acyclovir I.P.3% Sgm tube 11

MOXIFLOXACIN +PREDNISOLONE EYE DROP- Each vial to contain:

29 1598 Moxifloxacin 0.5%, Prednisolone Acetate 1%, 5mlvial 11

f-- 30 1599 MOXIFLOXACIN EYE OINT- Each tube : Moxifloxacin 0.5% Sgm tube 11

BESIFLOXACIN EYE DROP- Each ml to contain: Besifloxacin 0.6% {6mg/ml),

Excepients: Polycarbophil, Mannitol, Poloxamer 407, Sodium Chloride,

31 1912 Edetate Disodium Dihydrate, Sodium Hydroxide and water for injection 5ml bottle 11

32 1602 TRAVOPROST EYE DROP- Each vial: Travoprost 0.004% 2.5ml 12

1925 TRAVOPROST AND TIMOLOL EYE DROP- Each vial to contain: Travoprost

33 0.004%, Timolol 0.5% 2.5ml vial 12

ANTIBIOTIC EYE OINTMENT- Each gram to contain:Polymyxin B Sulphate

5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU Hydrocortisone 10

34 1211 mg. 5gm. Tube 13

POLYMIXIN, NEOMYCIN EYE OINT.- containing per gm. Polymixin B Sulphate

35 1251 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU 5gm. Tube 13

36 1212 FLURBIPROFEN EYE DROPS- Containing: Flurbiprofen 0.03% w/v 5ml. Vial 13

37 1594 EYE DROPS -Containing: Gatifloxacin Soln 0.3% w/v 5mlvial 13

Page 2 of 2

Employees' State Insurance Corporation

Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 142

Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020

lttem No I Drug Description

Firm Name Firm Rate/ unit Firm Packing Preference

1496 RABEPRAZOLE SODIUM+ MOSAPRIDE CITRATE CAP - Cap, Rabeprazole sodium 20mg, Mosapride Citrate 15mg sustained release

TORRENT 2.82/1 cap. 10Cap FIRST PHARMACEUTICALS LTD

Rupees two paisa eighty two only

I Packing

Description of stores accepted

1 cap.

Rabeprazole sodium IP 20 mg (as enteric coated pellets) VELOZ M SAME AS IN ITEM

12009 LANSOPRAZOLE 15MG TAB/CAP- Each orally disintegrated Tab 1 Tab/Cap /cap to contain: lansoprazole 15mg (as Enteric Coated pellets)

Cipla Ltd 4.2667/1 15 tab FIRST JUNIOR LANZOL 15MG Tab/Cap

Rupees four paisa two six six seven only

2053 Each Hard gelatin capsule contains: Rabeprazole Sodium IP 20 mg (as enteric coated pell!!ts) Domperidone IP 36 mg (as sustained release pelletes)

Corona Remedies Pvt 0.89/1 cap. Ltd

10Cap FIRST

Rupees zero paisa eighty nine only

SAME AS IN ITEM

1 cap.

MACRO

SAME AS IN ITEM

USV PRIVATE LIMITED

1.16/1 cap. 10tab SECOND Drego D

MICRO LABS LTD 1.65/1 cap.

Rupees one paisa sixteen only

10 cap THIRD

Rupees one paisa sixty five only

Page 1 of13

SAME AS IN ITEM

RABIROS-D SAME AS IN ITEM

I


Rate Schedule of Running Rate Contract No. U-25/1Z/14Z/Z017-Med V FOR RC 14Z

Valid from Thursday May 3'd 2018 to Saturday May z"d ZOZO

/Item No I Drug Description I Packing

Firm Name Firm Rate/ unit Firm Packing Preference Description of stores

I 1822 I LACTULOSE SYP- Each 15ml to contain : Lactulose lOgm

Abbott India Limited 70/ZOOml bot ZOO ml bott FIRST

Rupees seventy only

accepted

I 200ml bot

DUPHALAC SAME AS IN ITEM

OVERSEAS HEALTH 87 .35/ZOOml ZOO ml bott SECOND LAXDAY SYRUP CARE PVT LTD bot

PSYCHOTROPIC$ INDIA LIMITED

Rupees eighty seven paisa thirty five only

88.44/ZOOml bot

200ml bott THIRD

Rupees eighty eight paisa forty four only

/1823 I LACTULOSE SYP- Each 15ml to contain : Lactulose 10gm .

Abbott India Limited 150/450ml bot 450ml bott FIRST

Rupees one hundred fifty only

SAME AS IN ITEM

Lactopil

SAME AS IN ITEM

I 450ml bot

OUPHALAC SAME AS IN ITEM

PSYCHOTROPIC$ 192.88/450ml 4SOmlbott SECOND Lactopil INDIA LIMITED bot

SAME AS IN ITEM

Rupees one hundred ninety two paisa eighty eight only

16 ANTISPASMODIC DROPS/SUSPENSION - Each mi. to contain: 10 mi. Bot. Dicyclomine HellO mg, Activated Dimethicone 40mg.

PSYCHOTROPIC$ 10.46/10 mi. 10 ML bott FIRST Spaskid drop INDIA LIMITED Bot.

SAME AS IN ITEM

Rupees ten paisa forty six only

Page 2 of13




litem No I Drug Description I Packing

Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted

1346 DICYCLOMINE + MEFENAMIC TAB - Each Tab to contain: 1 Tab Dicyclomine 10mg., Mefenamic Acid 250mg.

PSYCHOTROPICS 0.45/1 Tab 10 tab FIRST Kolispas INDIA LIMITED

SAME AS IN ITEM

Rupees zero paisa forty five only

2056 Each tablet to contain Chlordiazepoxide Smg, Clidinium 1 tab Bromide 2.5mg

OVERSEAS HEALTH 2.56/1 tab 10 x 10tab FIRST SPASRAX CARE PVTLTD

SAME AS IN ITEM

Rupees two paisa fifty six only

Abbott Healthcare Private Limited

3.01/1 tab 10tab SECOND LIBRAX

Rupees three paisa one only

1991 LIVER DISORDERS SYP - Each l.Sml contains: DL-Methionine BP 100mg, Choline Dihydrogen Citrate NFXII 100mg, L-Leucine USP 19mg, L-lsoleucine USP 10mg ,L-Valine USP11mg ' Pyridoxine Hcl IP 1.5rng, Nicotinamide IP 22.Smg, Biotin USP O.lmg , Folic Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg, Inositol BP SOmg

TABLETS {INDIA} LIMITED

68.11/200ml bot

200ml bott FIRST

Rupees sixty eight paisa eleven only

Page 3 of13

SAME AS IN ITEM

200m! bot

NEUTROSEC LIQUID

SAME AS IN ITEM


Rate Schedule of Running Rate Contract No. U-25/12/142/::1.017-Med V FOR RC 142


litem No [ Drug Description


1992 LIVER DISORDERS TAB- Each tab to contain: DL-Methionine BP 200mg , Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-lsoleucine USP lOmg, L-Valine USP llmg, Pyridoxine Hydrochloride IP l.Smg,Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Acid IP 0.5 mg, Cyanocobalamin IP 3.0 meg, Inositol BP 50 mg

TABLETS (INDIA) LIMITED

4.88/1 tab 10tab FIRST

Rupees four paisa eighty eight only

1

577 j URSODESOXYCHOLIC ACID TAB - Each Ursodesoxycholic acid 150mg.

tab. to contain:

PSYCHOTROPICS 6.13/1 tab 10 tab FIRST INDIA LIMITED

Rupees she paisa thirteen only

[Packing


1 tab

NEUTROSEC

SAME AS IN ITEM

1 tab

Ursopil150

SAME AS IN ITEM

Corona Remedies Pvt 7.87/1 tab Ltd

lOtab SECOND URSOBILE 150

Rupees seven paisa eighty seven only

Abbott India Limited 7.96/1 tab 10 tab THIRD

Rupees seven paisa ninety six only

Page 4 of13

SAME AS IN ITEM

UDILIV 150 SAME AS IN ITEM




Llt~re=m~N~o ______________ _Lio~r~u~g~D~e~sc~nLp~ti~on~ _______________ ILP~a~c~W_n_~g ___________ ]


I 2057 I Each tab to contains: Ursodoxycholic Acid 300mg 11 tab

PSYCHOTROPIC$ 11.9/1 tab 15 tab FIRST Ursopil300 INDIA LIMITED

SAME AS IN ITEM

Rupees eleven paisa ninety only

Abbott India Limited 15.15/1 tab 15 tab SECOND UDILIV 300 SAME AS IN ITEM

Rupees fifteen paisa fifteen only

Corona Remedies Pvt 15.39/1 tab Ltd

10tab THIRD

Rupees fifteen paisa thirty nine only

URSOBILE 300

SAME AS IN ITEM

2058 Each enteric coated tablet contains: Pancreatin 170mg 1 tab Activated Dlmethicone 80mg

Abbott India Limited 6.77/1 tab 15 tab FIRST PANKREOFLAT

358

USV PRIVATE LIMITED

Rupees six paisa seventy seven only

HAEMORRHOIDAL CREAM - containing: Beclomethasone diproplonate 0.025 %, Phenylepherine Hydrochloride 0.1 %, Lignocaine hydrochloride 25 %.

29.6/20gm Tube

20gmtube FIRST

Rupees:twenty nine paisa sixty only

Page 5 of 13

SAME AS IN ITEM

20gmTube

Anovate Cream

SAME AS IN ITEM




lttem No I Drug Description


1856 TRAMADOL AND PARACETAMOL TAB/ CAP - Each tab/cap to contain:Tramadol 37.50 mg, Paracetamol 325mg

PSYCHOTROPICS INDIA LIMITED

1.08/1 tab/ cap 10 tab FIRST

Rupees one paisa eight only

I Packing


1 tab/ cap

Tromaml Extra

SAME AS IN ITEM

TROIKAA PHARMACEUTICALS LIMITED

1.4/1 tab/ cap 10 x 10 tab SECOND ZYROTRAM P RAPID

JOHNSON & JOHNSON PVT LTD

Rupees one paisa forty only

4.73/1 tab/ cap 15 tab THIRD

Rupees four paisa seventy three only

SAME AS IN ITEM

ULTRACET

SAME AS IN ITEM

1093 IBUPROFEN AND PCM ORAl SUSP • Each 5 ml to contain: 60ml bot Ibuprofen 100 mg., .F'aracetamol162.5 mg.

OVERSEAS HEALTH 10/60ml bot 60 ml bott CARE PVTLTD


10.8/GOml bot

Rupees ten only

60mlbott

FIRST IBUTOP

SAME AS IN ITEM

SECOND lbupil Plus

SAME AS IN ITEM

Rupees ten paisa eighty only

Page 6 of13




[ttemNo I Drug Description I Packing


1376 HYDROXY CHLOROQUINE TAB - Each tab to contain: Hydroxy 1 tab Chloroquine Sulfate 200mg

MICRO LABS LTD 2.33/1 tab 10 tab FIRST WIN FLAM SAME AS IN ITEM

Rupees two paisa thirty three only

OVERSEAS HEALTH CARE PVT LTD

3.5/1 tab 10 x 10 tab SECOND CARTIQUIN

WALLACE PHARMACEUTICALS PVTLTD

4.58/1 tab

Rupees three paisa fifty only

10tab THIRD

Rupees four paisa fifty eight only

11675 I ~RNOXICAM SR TAB- Each SR tab to contain: Lornoxicam 16

GLEN MARK 9.877/ltab 10 tab FIRST PHARMACEUTICALS LIMITED

Rupees nine paisa eight seven seven only

Page 7 of 13

SAME AS IN ITEM

OXCQ200

SAME AS IN ITEM

1 tab

FLEXILORSR

SAME AS IN ITEM


Rate Schedule of Running Rate Contract No. U-25/12/142./2017-Med V FOR RC 142

Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020

lttemNo I Drug Description I Packing


j1862 I FEBUXOSTAT TAB- Each tab to contain: Febuxostat 40mg I 1 tab

Ajanta Pharma Ltd 1.145/1 tab 10 tab FIRST Feburic 40 SAME AS IN ITEM

Rupees one paisa one four five only


1.74/1 tab 10tab SECOND Parustat-40

Rupees one paisa seventy four only

MICRO LABS LTD 2.02/1 tab 10tab THIRD

Rupees two paisa two only

SAME AS IN ITEM

XANURIX40 SAME AS IN ITEM

2024 PARACETAMOL 6SOMG TAB - Each Tab Paracetamol 650mg

to contains: 11 tab

MICRO LABS LTD 1,31/1 tab 1S tab FIRST DOLO 650 SAME AS IN ITEM

Rupees one paisa thirty one only

2082 Each tab to contain Dexketoprofen 25mg + Paracetamol 1 tab 325mg

Em cure Pharmaceuticals Limited

5.87/1 tab 10tab FIRST

Rupees five paisa eighty seven only

Page 8 of13

INFEN-P

SAME AS IN ITEM




[ttem No l Drug Description


2083 Aflibercept injection 40 mg I miAflibercept (r-DNA Origin) solution for intravitreal injection in ViaiEach pack contains: 1 vial and a 18 G Sterile filter needle 278 microliters/vial Each single dose vial provides a usable amount to deliver a single dose 50 microl.iters containing 2mg Aflibercept.

Bayer Zydus Pharma 40495/1 v1al 1 v1al and 18G sterile filter needle

FIRST Private Limited

l Packing


1 vial

Eylea Mfg.: Bayer AG, Mullerstrasse,Berlin, Germany SAME AS IN ITEM

Rupees forty thousand four hundred ninety five only

~

1866 ANALGESIC CREAM - Each tube to contain: Methyl salicylate 30% w/w, Menthol 10 % w/w, Camphor 4 % w/w Excipients q.s.

Sanof1 lnd1a L1m1ted 53.99/.30 gm tube

30gm tube FIRST

Rupees fifty three paisa ninety nine only

30 gm tube

comb1flam MS Cream

SAME AS IN ITEM

1432 OLOPATADIN EYE DROP Each ml to contain: Olopatadin Sml vial l.Omg

Ajanta Pharma Ltd 15/Sml vial Sml

Rupees fifteen only

Cipla Ltd 39.8/Sml vial SML

FIRST Olopatadine Hydrochloride Opthalmic Solution USP 0.1 PER w/v SAME AS IN ITEM

SECOND IF2 EYE DROPS SAME AS IN ITEM

Rupees thirty nine paisa eighty only

Page 9 of13




\ttemNo I Drug Description I Packing


1601 DORZOLAMIDE+TIMOLOL EVE DROP - Each vial to contain: Sml vial Dorzolamide 2% ,Timoloii.P. 0.5%

MICRO LABS LTD 114.24/Sml vial SML FIRST MISOPT EVE DROPS SAME AS IN ITEM

Cipla ltd

Rupees one hundred fourteen paisa twenty four only

190/Sml vial SML SECOND DOR20X T EVE DROPS SAME AS IN ITEM

Rupees one hundred ninety only

1923 CARBOXY METHYL CEL·l· Ul .. OSE EVE DROP - Each. ml to conta. in: 110m I vial Sodium Carboxy methyl cellulose Smg .

Cipla Ltd

MICRO LABS LTD

Ajanta Pharma Ltd

27.9/lOml vial 10ML FIRST ADD TEARS SAME AS IN ITEM

Rupees twenty seven paisa ninety only

29.12/lOml vial 10ML SECOND LUBhEX EYE DROPS SAME AS IN ITEM

Rupees twenty nine paisa twelve only

77/10ml vial 10 ml vial tHIRD

Rupees seventy seven only

AQUALUBE EYE DROP SAME AS IN ITEM

1924 DORZOLAMIDE EYE DROP - Each vial to contain: Dorzolamide Sml vial 2%

MICRO LABS LTD

Cipla Ltd

80.64/Sml vial SML FIRST MONOSOPT EYE DROPS SAME AS IN ITEM

Rupees eighty paisa Sixty four only

178/Sml vial SML SECOND DORZOX EVE DROPS SAME AS IN ITEM

Rupees one hundred seventy eight only

Page 10 of 13




lttemNo I Drug Description I Packing


11228

Cipla Ltd

1598

I ACYCLOVIR EYE OINT- Each tube to contain: Acyclovir I.P.3%

19.5/5gm tube 5 gm tube FIRST

Rupees nineteen paisa fifty only

I

MOXIFLOXACIN + PREDNISOLONE EYE DROP - Each ml

contain: Moxifloxacin 0.5%, Prednisolone Acetate 1%,

Ajanta Pharma Ltd 18.54/Sml vial 5 ML VAIL FIRST

Rupees eighteen paisa fifty four only

accepted

I Sgm tube

ACIVIR EYE OINTMENT SAME AS IN ITEM

to Sml vial

Moxifloxacin Plus Prednisolone Acetate Opthalmic Solution SAME AS IN ITEM

1599 MOXIFLOXACIN EYE OINT - Each tube to contain: Moxifloxacin Sgm tube 0.5%

Cipla Ltd 3S/5gmtube 5gmtube

Rupees thirty five only

FIRST MOXICIP EYE OINTMENT SAME AS IN ITEM

1912 BESIFLOXACIN EYE DROP • Each ml to contain: Besifloxacin Sml bottle 0.6% (6mg/ml)

Ajanta Pharma Ltd 85.5/5ml bottle 5 ML vial FIRST BESIX EYE DROP SAME AS IN ITEM

Rupees eighty five paisa fifty only

Page 11 of13 --

I

Employees' St·ate Insurance Corporation


Valid from Thursday May 3''d 2018 to Saturday May 2"d 2020

Lj l~re~m~N~o~ ______________ Lio~r~u~g~D~e=s=u~~~t~m~n~--------------~~~P~a=ck~m~g~ _________ :]


1602 TRAVOPROST EVE DROP- Each vial/ml to contain: Travoprost 2.5ml 0.004%

Ajanta Pharma Ltd 168.5/2.5ml 2.5 ml vial FIRST TOVAXO EVE DROP SAME AS IN ITEM

Cipla Ltd

ALCON

LABORATORIES {INDIA) PRIVATE

LIMITED

Rupees one hundred sixty eight paisa fifty only

269/2.5ml 2.5ML SECOND XOVATRA EYE DROPS SAME AS IN ITEM

Rupees two hundred sixty nine only

408.7/2.5ml 2.5ml THIRD

Rupees four hundred eight paisa seventy only

TRAVATAN Mfg.: S.A. Alcon Couvreur N. V.,

Belgium

SAME AS IN ITEM

I

1925 TRAVOPROST AND TIMOLOL EYE DROP - Each vial/ml to 2.5ml vial contain: Travoprost 0.004%, Timolol 0.5% J

Ajanta Pharma Ltd 172.80/2.5ml 2.5 ML VIAL FIRST TOVAXO T EVE DROP

ALCON

LABORATORIES

(INDIA) PRIVATE

LIMITED

vial SAME AS IN ITEM

Rupees one hundred seventy two paisa eighty only

550/2.5ml vial 2.5 miVial SECOND TRAVACOM Mfg.:

Rupees five hundred fifty only

Page 12 of13

S.A. Alcon Couvreur N.V.,

Belgium

SAME AS IN ITEM


Rate Schedule of Running Rate Contract No. U-25/12/:1.42/2017-Med V FOR RC 142

Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020

[Item No I Drug Description I Packing


1211 ANTIBIOTIC EYE OINTMENT- Each gram to contain:Polymyxin B Sulphate 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU Hydrocortisone 10 mg. in white sterilised petroleum jelly base.

GlaxoSmithKiine 33.17/5gm. Sgm Tube FIRST

Pharmaceuticals Ltd. Tube

Rupees thirty three paisa seventeen only

1251 POLYMIXIN, NEOMYCIN EYE OINT. - containing per gm. Polymixin B Sulphate 5000 IU Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU

GlaxoSm1thKhne 24.35/5gm. SgmTube FIRST Pharmaceuticals Ltd. Tube

Rupees twenty four paisa thirty five only

1212 FLURBIPROFEN EYE DROPS - Containing: Flurbiprofen 0.03% w/v

MICRO LABS LTD 14.45/Sml. Vial SML FIRST

Rupees fourteen paisa forty five only

[1594 I EYE DROPS- Containing: Gatifloxacln Soln0.3%w/v

Ajanta Pharma Ltd 34.25/Sml vial 5 ML VIAL FIRST

Rupees thirty four paisa twenty five only

Page 13of13

accepted

Sgm. Tube

Neosporin H Omtment

SAME AS IN ITEM

Sgm. Tube

. . Neosporm Ant1b1ot1c

Ointment SAME AS IN ITEM

5ml. Vial

FBN EYE DROPS SAME AS IN ITEM

fsmlvial

GATE EYE DROPS SAME AS IN ITEM

Documents

ESIC€¦ · esic central rate contract no. -142 for supply of drugs & dressings (valid from 3rd may, 2018 to 2"d may, 2020) drugs for gastro intestinal system drugs for musculo-skeletal